文献速递急性肾损伤慢性肾脏病

急性肾损伤恢复期胱抑素C估算肾小球滤过率与肌酐估算肾小球滤过率的比较

Comparing Cystatin C Estimated GFR With Creatinine Estimated GFR in Acute Kidney Injury Recovery.
PubMed 文献 · Kidney Int Rep · 2025-05-12

ARID前瞻性平行组队列研究在849例住院患者中比较急性肾损伤(AKI)后3个月基于胱抑素C的估算肾小球滤过率(eGFRcys)与基于肌酐的估算肾小球滤过率(eGFRcr)。eGFRcys低于eGFRcr,AKI组差异更明显,且eGFRcys将更多患者归类为慢性肾脏病(CKD)。在AKI组,较高的肌酐肌肉指数(CMI)与5年较低死亡率独立相关。

要点

  • AKI后3个月eGFRcys低于eGFRcr,AKI组差异更明显。
  • AKI组eGFRcys<60 ml/min per 1.73 m2者占69.6%,eGFRcr<60者占44.9%。
  • AKI组CMI较高与5年死亡率较低独立相关(校正HR 0.931)。

核心结论

  • AKI后3个月基于肌酐与基于胱抑素C的eGFR存在显著差异,两者差值与后续死亡率相关。
  • 需要进一步研究以确定AKI后患者评估的最佳方法。

研究设计与样本

  • AKI Risk in Derby(ARID)研究为前瞻性平行组队列研究。
  • 住院期间有和无AKI暴露的参与者按年龄、基线肾功能和糖尿病1:1匹配。
  • 849名参与者在入院后3个月比较eGFRcr与eGFRcys。
  • 评估CMI与5年结局(包括死亡率、心力衰竭和住院)的关联。

主要发现

  • eGFRcys低于eGFRcr:53.4(IQR 34.3-85.5)vs 68.4(IQR 52.5-84.7)ml/min per 1.73 m2,P < 0.001。
  • AKI组中eGFRcr < 60 ml/min per 1.73 m2者占44.9%,eGFRcys < 60 ml/min per 1.73 m2者占69.6%,P < 0.001。
  • AKI组中较高CMI与5年较低死亡率独立相关(校正风险比0.931 [0.874-0.992] mg/d per 1.73 m2,P = 0.03)。

局限性

  • 需要进一步研究以确定AKI后患者评估的最佳方法。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Current guidelines recommend creatinine-based estimated glomerular filtration rate (eGFRcr) to assess kidney recovery after acute kidney injury (AKI); however, this may be inaccurate because of loss of muscle mass. Cystatin C-based eGFR (eGFRcys) is an alternative that is not similarly affected. In addition, simple calculations (e.g., creatinine muscle index, CMI) incorporating the difference between eGFRcr and eGFRcys may indicate prognosis. We sought to determine whether eGFRcr differs from eGFRcys after AKI and whether CMI is associated with mortality. METHODS: The AKI Risk in Derby (ARID) study is a prospective parallel-group cohort study. Hospitalized participants with and without exposure to AKI were matched 1:1 for age, baseline kidney function, and diabetes. eGFRcr and eGFRcys at 3 months after admission were compared in 849 participants. Associations between CMI and outcomes, including mortality, heart failure, and hospitalization were assessed at 5 years. RESULTS: eGFRcys was lower than eGFRcr (53.4, [interquartile range, IQR: 34.3-85.5] vs. 68.4 [IQR: 52.5-84.7] ml/min per 1.73 m2, P < 0.001), with more pronounced differences in those with AKI. eGFRcys categorized more participants with chronic kidney disease (CKD) (in AKI group: eGFRcr < 60 ml/min per 1.73 m2 in 44.9%; eGFRcys < 60 ml/min per 1.73 m2 in 69.6%, P < 0.001). In the AKI group, higher CMI was independently associated with lower mortality at 5 years (adjusted hazard ratio: 0.931 [0.874-0.992] mg/d per 1.73 m2, P = 0.03). CONCLUSION: There are significant differences at 3 months after AKI in eGFR derived from creatinine versus cystatin C. The magnitude of difference between these estimates is associated with subsequent mortality. Further research is required to determine the optimal approach to patient assessment after AKI.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Horne KL, Packington R, Monaghan J, et al. Comparing Cystatin C Estimated GFR With Creatinine Estimated GFR in Acute Kidney Injury Recovery. Kidney Int Rep. 2025. PMID: 40814617. doi:10.1016/j.ekir.2025.05.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。